Go Deep
KNC Laboratories Co., Ltd.
KNC Laboratories Co., Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,539 | 12.4 | 0.70 | 0.26 | 772.45 |
| Oct 2026 | 23,525 | 12.4 | 0.71 | 0.26 | 773.38 |
KNC Laboratories Co., Ltd. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 2,118,047,000.0 | 3,499,920,000.0 | 2,219,581,000.0 | 1,679,287,000.0 |
| Net Profit | 41,028,000.0 | 660,526,000.0 | 104,636,000.0 | 12,343,000.0 |
| EPS | 5.3 | — | — | — |
KNC Laboratories Co., Ltd. Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 9,093,706,000.0 | 8,178,920,000.0 | 9,154,577,000.0 | 8,628,009,000.0 |
| Net Profit | 766,199,000.0 | 737,329,000.0 | 1,493,023,000.0 | 1,542,843,000.0 |
| EPS | 99.0 | 95.4 | 193.5 | 200.1 |
KNC Laboratories Co., Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 21,644,090,000.0 | 20,152,445,000.0 | 18,621,632,000.0 | 15,404,512,000.0 | — |
| Total Liabilities | 7,563,549,000.0 | 6,632,218,000.0 | 5,534,785,000.0 | 3,659,452,000.0 | — |
| Total Equity | 14,080,541,000.0 | 13,520,227,000.0 | 13,086,847,000.0 | 11,745,060,000.0 | — |
Owes vs Owns
KNC Laboratories Co., Ltd. owed ¥0.34 for every ¥1 it owned in Jun 2026, up from ¥0.24 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.34× | 0.35× | 0.33× | 0.30× | 0.24× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
KNC Laboratories Co., Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 10.0%Receivables 8.0%Inventory 15.2%Fixed assets (tangible) 56.7%Long-term investments 1.5%Other assets 8.2%
How it's funded — Mar 2026
Short-term debt 5.1%Long-term debt 11.5%Payables 2.0%Other liabilities 16.3%Shareholders' equity 65.1%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,173.3 | 2,385.6 | 3,311.5 | 2,297.3 |
| Receivables | 1,734.7 | 2,407.6 | 2,626.0 | 2,790.7 |
| Inventory | 3,290.6 | 2,541.8 | 2,518.3 | 2,279.9 |
| Fixed assets (tangible) | 12,277.2 | 11,147.0 | 8,474.8 | 7,199.8 |
| Intangible assets | 61.0 | 51.6 | 53.4 | 63.5 |
| Long-term investments | 333.0 | 232.6 | 344.3 | 221.5 |
| Other assets | 1,774.3 | 1,386.2 | 1,293.2 | 551.8 |
| Liabilities & equity | ||||
| Short-term debt | 1,102.7 | 852.4 | 658.3 | 940.0 |
| Long-term debt | 2,493.9 | 2,266.6 | 1,311.7 | 596.7 |
| Payables | 429.7 | 346.3 | 300.2 | 305.6 |
| Other liabilities | 3,537.2 | 3,166.9 | 3,264.6 | 1,817.1 |
| Shareholders' equity | 14,080.5 | 13,520.2 | 13,086.8 | 11,745.1 |
| Net tangible assets | 14,019.6 | 13,468.7 | 13,033.4 | 11,681.5 |
KNC Laboratories Co., Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 2,262,650,000.0 | 1,487,123,000.0 | 3,204,538,000.0 | 1,993,942,000.0 | — |
| Investing Activities | -2,697,301,000.0 | -3,322,708,000.0 | -2,369,133,000.0 | -1,146,863,000.0 | — |
| Financing Activities | 222,350,000.0 | 909,599,000.0 | 178,866,000.0 | -523,391,000.0 | — |